Literature DB >> 25748686

Efficacy and toxicity of dexamethasone vs methylprednisolone-long-term results in more than 1000 patients from the Russian randomized multicentric trial ALL-MB 2002.

A Karachunskiy1,2, J Roumiantseva1,2, S Lagoiko1, C Bührer3, G Tallen3, O Aleinikova4, O Bydanov4, N Korepanova1, L Bajdun5, T Nasedkina1,6, A von Stackelberg3, G Novichkova1,2, A Maschan1,2, D Litvinov1,2, N Myakova1, N Ponomareva5, K Kondratchik2,7, L Fechina8, O Streneva8, N Judina9, G Scharapova10, A Shamardina11, I Gerbek12, A Shapochnik13, A Rumjanzew1,2, G Henze1,3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25748686     DOI： 10.1038/leu.2015.63

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  14 in total

1.  In vitro determination of relative corticosteroid potency.

Authors:  H L Cantrill; S R Waltman; P F Palmberg; H A Zink; B Becker
Journal:  J Clin Endocrinol Metab       Date:  1975-06       Impact factor: 5.958

2.  Dexamethasone compared to prednisolone for adults with acute lymphoblastic leukemia or lymphoblastic lymphoma: final results of the ALL-4 randomized, phase III trial of the EORTC Leukemia Group.

Authors:  Boris Labar; Stefan Suciu; Roel Willemze; Petra Muus; Jean-Pierre Marie; Georges Fillet; Zwi Berneman; Branimir Jaksic; Walter Feremans; Dominique Bron; Harm Sinnige; Martin Mistrik; Gerard Vreugdenhil; Robrecht De Bock; Damir Nemet; Caroline Gilotay; Sergio Amadori; Theo de Witte
Journal:  Haematologica       Date:  2010-04-07       Impact factor: 9.941

3.  Improved response with higher corticosteroid dose in children with acute lymphoblastic leukemia.

Authors:  C L Schwartz; E B Thompson; R D Gelber; M L Young; D Chilton; H J Cohen; S E Sallan
Journal:  J Clin Oncol       Date:  2001-02-15       Impact factor: 44.544

Review 4.  Glucocorticoid use in acute lymphoblastic leukaemia.

Authors:  Hiroto Inaba; Ching-Hon Pui
Journal:  Lancet Oncol       Date:  2010-10-12       Impact factor: 41.316

Review 5.  Dexamethasone versus prednisone for induction therapy in childhood acute lymphoblastic leukemia: a systematic review and meta-analysis.

Authors:  O Teuffel; S P Kuster; S P Hunger; V Conter; J Hitzler; M-C Ethier; P S Shah; J Beyene; L Sung
Journal:  Leukemia       Date:  2011-04-29       Impact factor: 11.528

6.  Comparison of the antileukemic activity in vitro of dexamethasone and prednisolone in childhood acute lymphoblastic leukemia.

Authors:  G J Kaspers; A J Veerman; C Popp-Snijders; M Lomecky; C H Van Zantwijk; L M Swinkels; E R Van Wering; R Pieters
Journal:  Med Pediatr Oncol       Date:  1996-08

7.  Results of the first randomized multicentre trial on childhood acute lymphoblastic leukaemia in Russia.

Authors:  A Karachunskiy; R Herold; A von Stackelberg; N Miakova; A Timakow; T Mahortih; L Bajdun; A Maschan; L Fechina; A Shamardina; S Dudkin; V Lebedev; S Varfolomeeva; V Timofeeva; J Roumiantseva; N Chipsanova; A Rumjanzew; G Henze
Journal:  Leukemia       Date:  2008-03-27       Impact factor: 11.528

8.  Differences in cerebrospinal fluid penetration of corticosteroids: possible relationship to the prevention of meningeal leukemia.

Authors:  F M Balis; C M Lester; G P Chrousos; R L Heideman; D G Poplack
Journal:  J Clin Oncol       Date:  1987-02       Impact factor: 44.544

9.  Dexamethasone (6 mg/m2/day) and prednisolone (60 mg/m2/day) were equally effective as induction therapy for childhood acute lymphoblastic leukemia in the EORTC CLG 58951 randomized trial.

Authors:  Carine Domenech; Stefan Suciu; Barbara De Moerloose; Françoise Mazingue; Geneviève Plat; Alina Ferster; Anne Uyttebroeck; Nicolas Sirvent; Patrick Lutz; Karima Yakouben; Martine Munzer; Pierre Röhrlich; Dominique Plantaz; Frederic Millot; Pierre Philippet; Nicole Dastugue; Sandrine Girard; Hélène Cavé; Yves Benoit; Yves Bertrandfor
Journal:  Haematologica       Date:  2014-04-11       Impact factor: 9.941

10.  Risk group assignment differs for children and adults 1-45 yr with acute lymphoblastic leukemia treated by the NOPHO ALL-2008 protocol.

Authors:  Nina Toft; Henrik Birgens; Jonas Abrahamsson; Per Bernell; Laimonas Griškevičius; Helene Hallböök; Mats Heyman; Mette Skov Holm; Erik Hulegårdh; Tobias Wirenfeldt Klausen; Hanne V Marquart; Olafur Gísli Jónsson; Ove Juul Nielsen; Petter Quist-Paulsen; Mervi Taskinen; Goda Vaitkeviciene; Kim Vettenranta; Ann Åsberg; Kjeld Schmiegelow
Journal:  Eur J Haematol       Date:  2013-04-02       Impact factor: 2.997
View more
  2 in total

1.  One-point flow cytometric MRD measurement to identify children with excellent outcome after intermediate-risk BCP-ALL: results of the ALL-MB 2008 study.

Authors:  Alexander Popov; Guenter Henze; Julia Roumiantseva; Oleg Budanov; Mikhail Belevtsev; Tatiana Verzhbitskaya; Elena Boyakova; Liudmila Movchan; Grigory Tsaur; Maria Fadeeva; Svetlana Lagoyko; Liudmila Zharikova; Natalia Miakova; Dmitry Litvinov; Olga Khlebnikova; Olga Streneva; Elena Stolyarova; Natalia Ponomareva; Galina Novichkova; Larisa Fechina; Olga Aleinikova; Alexander Karachunskiy
Journal:  J Cancer Res Clin Oncol       Date:  2022-09-28       Impact factor: 4.322

2.  Reduced vs. standard dose native E. coli-asparaginase therapy in childhood acute lymphoblastic leukemia: long-term results of the randomized trial Moscow-Berlin 2002.

Authors:  Alexander Karachunskiy; Gesche Tallen; Julia Roumiantseva; Svetlana Lagoiko; Almira Chervova; Arend von Stackelberg; Olga Aleinikova; Oleg Bydanov; Lyudmila Bajdun; Tatiana Nasedkina; Natalia Korepanova; Sergei Kuznetsov; Galina Novichkova; Marina Goroshkova; Dmitry Litvinov; Natalia Myakova; Natalia Ponomareva; Evgeniya Inyushkina; Konstantin Kondratchik; Julia Abugova; Larisa Fechina; Oleg Arakaev; Alexander Karelin; Vladimir Lebedev; Natalia Judina; Gusel Scharapova; Irina Spichak; Anastasia Shamardina; Olga Ryskal; Alexander Shapochnik; Alexander Rumjanzew; Joachim Boos; Günter Henze
Journal:  J Cancer Res Clin Oncol       Date:  2019-03-06       Impact factor: 4.553
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.